Liposomes for the sustained drug release in vivo
- PMID: 2223816
- DOI: 10.1016/0005-2736(90)90440-y
Liposomes for the sustained drug release in vivo
Abstract
New lipidic carriers suitable for the sustained drug release in vivo are presented. They consist of middle sized, compact phospholipid vesicles with one or up to few lipid bilayers which are sterically stabilized with a small amount of large-head phospholipids. As an example, phosphatidylcholine (PC) liposomes casted with up to 10 mol% of phosphatidylethanolamine with a covalently attached polyethyleneglycol 5000 headgroup (PE-PEG) are discussed. Such vesicles exhibit a very long circulation time after an i.v. administration in mice; the improvement over pure phosphatidylcholine liposomes within the first 24 h exceeds 8000%, at this point nearly 25% of the applied PE-PEG liposomes being still in the circulation. This advantage is a consequence of reduced phagocytosis of the lipidic carriers, as shown by an in vitro assay with blood monocyte cells in the flow cytometric experiments. For example, after 6 h incubation with THP-1 monocyte cells in human plasma the difference between the uptake of standard distearoylphosphatidylcholine (DSPC) and novel liposomes containing 10% distearoylphosphatidylethanolamine-PEG is by 1000%. Vesicles with 2.5 mol% DSPE-PEG are also taken-up via phagocytosis relatively slowly. But the latter vesicles, moreover, retain most of the enclosed model-drug carboxyfluorescein after an incubation in plasma. The rate of permeation of the encapsulated substance from such DSPE-PEG liposomes is below 2.4% per h. This is by approximately a factor of two less than for pure DSPC liposomes; vesicles with a higher PE-PEG content are inferior in this respect. Long circulation time and high retention of the newly developed liposomes open up ways for the future systemic use as such stabilized drug carriers for the therapeutic applications in vivo.
Similar articles
-
Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol).Biochim Biophys Acta. 1992 Sep 22;1128(1):44-9. doi: 10.1016/0005-2760(92)90255-t. Biochim Biophys Acta. 1992. PMID: 1390877
-
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.Biochim Biophys Acta. 2002 Apr 12;1561(2):188-201. doi: 10.1016/s0005-2736(02)00345-0. Biochim Biophys Acta. 2002. PMID: 11997119
-
Molecular mechanism of the lipid vesicle longevity in vivo.Biochim Biophys Acta. 1993 Mar 14;1146(2):157-68. doi: 10.1016/0005-2736(93)90351-y. Biochim Biophys Acta. 1993. PMID: 8452853
-
Sterically stabilized liposomes.Biochim Biophys Acta. 1992 Aug 14;1113(2):171-99. doi: 10.1016/0304-4157(92)90038-c. Biochim Biophys Acta. 1992. PMID: 1510996 Review.
-
Pharmacokinetics of lipid-drug conjugates loaded into liposomes.Eur J Pharm Biopharm. 2018 Jul;128:188-199. doi: 10.1016/j.ejpb.2018.04.003. Epub 2018 Apr 18. Eur J Pharm Biopharm. 2018. PMID: 29678733 Review.
Cited by
-
Advancements in Engineering Planar Model Cell Membranes: Current Techniques, Applications, and Future Perspectives.Nanomaterials (Basel). 2024 Sep 13;14(18):1489. doi: 10.3390/nano14181489. Nanomaterials (Basel). 2024. PMID: 39330645 Free PMC article. Review.
-
HSPiP and QbD oriented optimized stearylamine-elastic liposomes for topical delivery of ketoconazole to treat deep seated fungal infections: In vitro and ex vivo evaluations.Int J Pharm X. 2024 Aug 26;8:100279. doi: 10.1016/j.ijpx.2024.100279. eCollection 2024 Dec. Int J Pharm X. 2024. PMID: 39282055 Free PMC article.
-
In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis.Pharmaceutics. 2023 Apr 6;15(4):1163. doi: 10.3390/pharmaceutics15041163. Pharmaceutics. 2023. PMID: 37111648 Free PMC article.
-
SREKA-targeted liposomes for highly metastatic breast cancer therapy.Drug Deliv. 2023 Dec;30(1):2174210. doi: 10.1080/10717544.2023.2174210. Drug Deliv. 2023. PMID: 36752075 Free PMC article.
-
Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy.Cancer Cell Int. 2022 Oct 18;22(1):323. doi: 10.1186/s12935-022-02743-3. Cancer Cell Int. 2022. PMID: 36258195 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials